Journal
British Journal of Cancer
Publication Date
2018
Volume
119
Issue
9
Inclusive Pages
1086-1093
Document Type
Open Access Publication
DOI
10.1038/s41416-018-0235-2
Rights and Permissions
Pamela Munster, et al. Safety and pharmacokinetics of MM-302, a HER2-targeted antibody–liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: A phase 1 dose-escalation study. 2018. British Journal of Cancer, 119(9): 1086-1093. © Cancer Research UK 2018. www.bjcancer.com. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
Recommended Citation
Munster, Pamela; Krop, Ian E.; LoRusso, Patricia; Ma, Cynthia; Siegel, Barry A.; Shields, Anthony F.; Molnár, István; Wickham, Thomas J.; Reynolds, Joseph; Campbell, Karen; Hendriks, Bart S.; Adiwijaya, Bambang S.; Geretti, Elena; Moyo, Victor; and Miller, Kathy D., "Safety and pharmacokinetics of MM-302, a HER2-targeted antibody–liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: A phase 1 dose-escalation study." British Journal of Cancer. 119, 9. 1086-1093. (2018).
https://digitalcommons.wustl.edu/open_access_pubs/7296
